Group items tagged

The primary purpose of the ASRM and SREI Research Grant Programs is to provide funds for new investigators to establish independent research programs. New investigators are those who have completed their training within the past three years and have independent faculty appointments at the commencement of the research. In special cases, ASRM will consider applications for bridge funding (i.e., between grant funding periods) for projects that are of benefit to other members of the Society, or for funding of new, highly innovative research projects by established investigators. Both the ASRM Research Grants, which are funded by the ASRM, and the SREI Research Grants, which are funded by SREI, are reviewed by the ASRM Research Committee. Grants in amounts of $10,000 to $50,000 will be considered for funding by the ASRM Board of Directors on an annual basis. A total of $200,000 is available for 2016. The SREI Board of Directors will fund one grant of up to $40,000. Funds are available for project expenses, technical assistance, patient expenses, research supplies and durable laboratory equipment. Up to ten percent (10%) of funds may be used for indirect costs or institutional overhead in circumstances deemed to be extraordinary by the Research Committee. Research grant funds may be expended over a 2-year time interval. If residual funds remain after 2 years, the principal investigator can apply for a no-cost extension. An individual should indicate which grant(s) he/she is applying for though he/she is eligible to receive only one grant.

The intent of the FY17 ERP IDA is to solicit research to understand the magnitude and underlying mechanisms of PTE. The FY17 ERP IDA offers two levels of funding. Funding Level I is intended to support high-risk or high-gain research from Principal Investigators (PIs) at or above the level of a postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). Note that PIs submitting Funding Level I applications will be required to verify their eligibility for this award. Funding Level II is intended to support a more mature, hypothesis-driven research project. To be considered for an FY17 ERP IDA Funding Level II, the PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). While not required, applications to either Funding Level I or II should provide relevant preliminary data. Preliminary data for either Funding Level may come from the PI's published work, pilot data, or from peer-reviewed literature. The requested budget level should be appropriate for the scope of research proposed.For Funding Level I:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $300,000. The maximum period of performance is 2 years. For Funding Level II:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $500,000. The maximum period of performance is 3 years. FY17 ERP IDA Focus Areas: The research impact for the FY17 ERP IDA is expected to benefit the military, Veteran, and civilian communities.

The Fund recognizes that young investigators may find it difficult to remain in pediatric research because of a lack of funding. Therefore, the purpose of this program is to encourage the development of medical research in child health by awarding small grants to new researchers, helping them gain a foothold in this important area. The goal is to fund applicants who will go on to be independent investigators. The Fund will make up to 30 awards total with two funding cycles (15 awards each). The Fund is open to a wide variety of research topics. We do not focus on a particular ​disease, but all our funded projects deal directly with children's health. In the Early Career Award Program, the Fund is particularly interested in applicants that show great potential to impact that field of children's health through medical research. Both an applicant's aptitude and inclination toward research are considered. The quality of the mentor and the mentoring relationship are also considered to be important predictors of success.

Depending on availability of funds, NOAA Sea Grant expects to have available about $1,600,000 for each of FY 2015 and FY 2016 for a national competition to fund marine aquaculture extension and technology transfer efforts, as part of the overall plan to support the development of environmentally and economically sustainable ocean, coastal and Great Lakes aquaculture. Aquaculture that occurs in the Great Lakes or its coastal zone is considered marine aquaculture for this competition. This Federal Funding Opportunity includes information on application and criteria for aquaculture extension proposals requesting a maximum of $300,000 in total federal funding for up to a two-year period. Matching funds are required. Proposals are required to include a partnership (e.g., with local community governments, state and Federal agencies, regional management efforts, industry, non-governmental organizations). Awards are anticipated to start no later than September 1, 2015. Additional proposals from this competition may be selected for funding in subsequent fiscal years, subject to the availability of funds.

The OPORP Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding of and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies. Studies are sought that: * Compare different patient care approaches. * Include patient-centric outcome assessments. * Have the potential to generate new knowledge that can be developed into new clinical practice guidelines, and/or new prescription algorithms for prosthetic and orthotic devices. * Have the potential to develop new technology for improved prosthetic and orthotic devices, therefore improving patient outcomes. * Provide information on quality of life, reintegration, and/or return to duty/return to work as it pertains to those patients who use a prosthetic or orthotic device due to limb trauma. All applications must demonstrate direct relevance to Service Members and Veterans with traumatic extremity injury and/or amputation using prosthetics and orthotic devices. Examples of studies that are appropriate for submission to the FY14 OPORA include, but are not limited to, examination of the

he intent of the FY18 ERP IDA is to solicit research to understand the magnitude and underlying mechanisms of PTE related to the ERP's mission (see Section II.A, Program Description). The FY18 ERP IDA offers two levels of funding. Funding Level I is intended to support high-risk or high-gain applications with Principal Investigators (PIs) at or above the level of a postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). Note that organizations submitting Funding Level I applications will be required to verify their eligibility for this award. Funding Level II is intended to support a more mature, hypothesis-driven research project. For an FY18 ERP IDA Funding Level II application, the PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). While not required, applications to either Funding Level I or II should provide relevant preliminary data. Preliminary data for either Funding Level may come from the PI's published work, pilot data, or from peer-reviewed literature. The requested budget level should be appropriate for the scope of research proposed. Research proposed to either the Epidemiology or Longitudinal Studies Focus Area, described below, will require the development of an Epidemiological/Longitudinal Studies Research Statement.

The AACR NextGen Grants for Transformative Cancer Research represent the AACR's flagship funding initiative to stimulate highly innovative research from young investigators. This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. The grants provide $450,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants, research/laboratory supplies, equipment, travel applicable to the research project, publication charges for manuscripts that pertain directly to the funded project, other research expenses, and indirect costs.

The AACR NextGen Grants for Transformative Cancer Research represent the AACR's flagship funding initiative to stimulate highly innovative research from young investigators. This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. The grants provide $450,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants, research/laboratory supplies, equipment, travel applicable to the research project, publication charges for manuscripts that pertain directly to the funded project, other research expenses, and indirect costs.

Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources.

The Melanoma Research Foundation is accepting applications from emerging and established scientific investigators for research projects that explore new avenues in melanoma biology, prevention and treatments, with the goal of finding a cure. The foundation makes grants in four areas: Career Development Awards, Established Investigator Awards, Career Investigator CURE OM Awards, and Established Investigator CURE OM Awards. Career Development Awards provide funding of up to $50,000 a year for two years to junior investigators who are beginning a research career emphasizing melanoma-related projects and have not yet secured strong federal funding for their research. Established Investigator Awards provide funding of up to $100,000 a year for two years to established melanoma researchers or senior researchers working in closely related fields who wish to move into melanoma research. Career Development CURE OM Awards provide funding of up to $50,000 a year for two years to junior investigators in the ocular/uveal melanoma field. Established Investigator CURE OM Awards provides funding of up to $100,000 a year for two years to established ocular/uveal melanoma researchers, or senior researchers.

The research endowment has been made possible by charitable funds and individual donations derived from the annual campaign, specifically targeted for research. The intent of the research endowment is to use a portion of the interest derived from these funds to support basic and applied research in exercise science. The primary goal is to fund mechanistic, hypothesis driven, basic and applied research. A $10,000 grant is available and is applicable to all relevant fields of exercise science. Funding is primarily targeted for new or junior investigators, within 7 years of attaining a terminal degree (e.g., Ph.D., Ed.D.). It is the intent of this grant to provide seed money support after which further funding would be sought from other sources. Only one application per person is allowed.

FSH Society research and fellowship grant awards provide vital start-up  funding for investigators in FSHD and research projects on FSHD. The research milestones and insights gained are demonstrably significant. The fellowship program allows innovative and entrepreneurial research to develop and ultimately to be able to attract funding from large funding sources such as the US National Institutes of Health (NIH). The FSH Society meets an important need in funding and developing new ideas and supporting new investigators in FSHD research by giving them the funds needed to develop data and to carry their ideas to the next stage of development.

To further scientific and technological cooperation between the scientific communities of Germany and the United States, a Letter of Intent was signed on May 27, 2014 to enable U.S.-based scientists and engineers with NSF-funded CAREER awards to pursue research collaboration with colleagues supported through German Research Foundation (DFG) grants. Connecting researchers with complementary strengths and shared interests promotes scientific progress in solving some of the world's most vexing problems. This international research opportunity is mutually beneficial to the U.S. participants and their hosts through cooperative activities during research visits and also by establishing international research partnerships to enrich future research activities in Germany and the U.S. Under the Letter of Intent, the DFG identifies DFG-funded research groups who wish to host CAREER awardees for research visits of up to one year in connection with their DFG funding. This Dear Colleague Letter (DCL) invites current CAREER awardees to apply for supplemental funding to support travel for research visits to any identified, appropriate DFG-funded research group. Further, the DCL gives instructions on how to apply and other relevant policies and requirements.

The SCIMS program is designed to provide a multidisciplinary system of rehabilitation care specifically to meet the needs of individuals with SCI. To be eligible for a SCI Model Systems grant, an applicant institution must encompass a continuum of care for people with SCI, including emergency medical services, acute care services, acute medical rehabilitation services, and post-acute services. For purposes of this program, SCI is defined as a clinically discernible degree of neurologic impairment of the spinal cord following a traumatic event. NIDILRR currently supports 14 SCIMS centers through this program. The funding for these Centers is primarily used to conduct SCI research and to collect and send data to the SCIMS longitudinal database. SCIMS Centers will be funded at varying amounts up to the maximum award based on the numbers of subjects eligible for follow-up in the existing SCIMS longitudinal database. Existing centers with significantly larger numbers of subjects will receive higher funding within the specified range, as determined by NIDILRR after the applicant is selected for funding. Applicants provide detailed budgets for each research project and for data collection costs associated with the longitudinal database. Funding will be determined individually for each successful applicant, up to the maximum allowed, based upon the documented workload associated with the follow-up data collection, the other costs of the grant, and the overall budgetary limits of the program

Sigma Xi, a society of research scientists and engineers that rewards excellence in research and cooperation among scientists in all fields, has been providing undergraduate and graduate students with valuable educational experiences and financial support for more than eighty years. By encouraging close working relationships between students and faculty, the society promotes scientific achievement through hands-on learning. Through the Sigma Xi Grants-in-Aid of Research program, the society awards grants of up to $1,000 to students from all areas of the sciences and engineering. Designated funds from the National Academy of Sciences allow for grants of up to $5,000 for astronomy research and $2,500 for vision-related research. Funding can support travel expenses or nonstandard laboratory equipment necessary to complete a specific research project. While membership in Sigma Xi is not a requirement for applying for funding, approximately 75 percent of Grants-in-Aid of Research funds are restricted for use by dues-paying student members or students whose project advisor is a dues-paying member. Students from any country are eligible to receive funding. Complete program guidelines and application instructions are available on the Sigma Xi Web site.

The purpose of this funding opportunity is to support important "legacy" resources developed as a result of NIGMS research activities that are central to the mission of NIGMS and demonstrate a high value to a community of researchers that NIGMS supports, but are no longer eligible for support under their original initiatives. It is also expected that these resources are not eligible for support by other Institutes'/Centers' funding opportunity announcements, and not yet self-sustaining or ready for commercialization. For this initiative, a resource is defined as a non-hypothesis-driven activity that is available to any qualified investigator and provides data, materials, tools, or services considered essential to making the most timely, high quality, and cost-efficient progress in a field. This funding opportunity is designed to support the continuation of existing resources, not to develop new ones. The support requested must be for funding of maintenance activities only, and not for research activities. Under this limited program, only NIGMS-sponsored "legacy" resources that cannot be renewed under their initial funding activity are eligible. Up to three years' support can be requested while plans to transition to a more permanent form of support are implemented.

This TRI RFA is soliciting applications for its Postdoctoral Fellowship Program. Postdoctoral Fellowships will be competitively awarded in any laboratory in the U.S. conducting biomedical/biotechnological research aligned with TRI's mission and goals (Section A). Applications will be screened for compliance and undergo a scientific/technical peer-review by an external peer-review committee consisting of a number of eminent scientists that are familiar with space biomedical/biotechnological research. Relevance to TRI's and NASA's programmatic needs and goals will also be evaluated by TRI management. Selections will be performed by the TRI Selection Official. The award is for two years of funding with an optional, competitively awarded third year of funding that may be available depending on existing TRI resources. Requests for a third year of funding will take into account the awardee's performance during the first two years of funding and be evaluated via external peer-review and also by TRI's Executive Council (TRIEC). All researchers, regardless of support by NASA or TRI, can serve as Mentors for this competitive funding.

Grants are made by the Board of Trustees of Ohio Cancer Research taking into account studies and recommendations of the Scientific Review Committee. Grants are available to investigators in either nonprofit or for-profit institutions, offices or clinics within the State of Ohio. However, grants to investigators working for profit-making organizations may not include funds for capital equipment. Grants are made with the stipulation of their use by a particular individual or group who are known as the principal investigator in support of a specific program of research under his/her/their direction. Full professors or their equivalent are not eligible. Only tenure track, junior faculty or equivalent scientific staffs are generally considered as appropriate. Postdoctoral fellows, Research, research assistants, and graduate students are ineligible to apply as P.I.'s, but they may be included as support staff. The P.I. must show evidence of independence. Applicants must be within six years of their first independent research or faculty appointment. Well established investigators should not submit projects related to their current area of research. Investigators previously funded by Ohio Cancer Research must provide justification that this application is significantly different from the previously funded project. Information regarding the results of the previously funded proposal and the P.I.'s success in obtaining further national funding must also be provided. Grants awarded by Ohio Cancer Research are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.

The vision for the Human BioMolecular Atlas Program (HuBMAP) is to catalyze development of a framework for mapping of the human body at high resolution to transform our understanding of tissue organization and function. This will be achieved by: Accelerating the development of the next generation of tools and techniques for constructing high resolution spatial tissue maps that quantify multiple types of biomolecules either sequentially or simultaneously; Generating foundational 3D tissue maps using validated high-content, high-throughput imaging and omics assays; Establishing an open data platform that will develop novel approaches to integrating, visualizing and modelling imaging and omics data to build multi-dimensional maps, and making data rapidly findable, accessible, interoperable, and reusable by the global research community; Coordinating and collaborating with other funding agencies, programs, and the biomedical research community to build the framework and tools for mapping the human body; Supporting pilot projects that demonstrate the value of the resources developed by the program to study individual variation and tissue changes across the lifespan and the health-disease continuum. This program is funded through the NIH Common Fund as a short-term, goal-driven strategic investment, with deliverables intended to catalyze research across multiple biomedical research disciplines. The NIH Common Fund supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress.

This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK.The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases.DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.

This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK.The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases.DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.